drugset / Trial / NCT05794958
Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a phase Ib study to establish safety of Axi-Cel-2 in patients with Large B Cell Lymphoma (LBCL) who are at high risk of relapse.
Timeline
- Start
- 2023-05-23
- Primary completion
- 2038-04-01
- Completion
- 2038-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Axicabtagene Ciloleucel | Cell therapy | 500000 cells/kg | — |